Growth Hormone Deficiency Market Analysis and Global Forecast 2023-2033

Growth Hormone Deficiency Market Overview

Growth Hormone Deficiency Market Size is expected to reach USD 6.21 Billion by 2033. The Growth Hormone Deficiency industry size accounted for USD 18.33 Billion in 2023 and is expected to expand at a compound annual growth rate (CAGR) of 4.21% from 2023 to 2033. The growth hormone deficiency market focuses on the treatment of conditions where the body does not produce sufficient growth hormone, leading to stunted growth and other health issues. This market includes diagnostic tests and therapeutic treatments such as recombinant growth hormone therapies. Key drivers include increasing awareness of the condition, advancements in biotechnology, and rising prevalence of growth hormone deficiency. The market is segmented by treatment type, end user (hospitals, clinics, and home care settings), and geography. Growth is fueled by innovations in drug formulations and delivery systems, as well as expanding healthcare infrastructure.

Global Growth Hormone Deficiency Market Synopsis

COVID-19 Impact Analysis

The COVID-19 pandemic has led to supply chain disruptions leading to supply shortages or lower demand in the Growth Hormone Deficiency market. The travel restrictions and social-distancing measures have resulted in a sharp drop in consumer and business spending and this pattern is to continue for some time. The end-user trend and preferences have changed due to the pandemic and have resulted in manufacturers, developers, and service providers to adopt various strategies to stabilize the company.

Global Growth Hormone Deficiency Market Dynamics

The major factors that have impacted the growth of Growth Hormone Deficiency are as follows:

Drivers:

⮚      Advancements in Biotechnology

Innovations in biotechnology, such as the development of recombinant DNA technology, have led to the creation of more effective and safer growth hormone therapies. These advancements have expanded treatment options and improved patient outcomes, contributing to market growth.

Restraint:

• Adverse Effects and Safety Concerns

Although generally safe, growth hormone treatments can have side effects such as joint pain, fluid retention, and increased risk of diabetes. Concerns about long-term safety and potential adverse effects can impact patient compliance and healthcare provider recommendations.

Opportunity:

⮚      Personalized Medicine

The trend towards personalized medicine offers opportunities to tailor growth hormone treatments based on individual genetic profiles and specific patient needs. Personalized approaches can improve treatment outcomes and drive demand for customized therapeutic solutions.

 Growth Hormone Deficiency Market Segment Overview

By Brands

Based on the Brands, the market is segmented based on Genotropin, Norditropin, Humatrope, Saizen, Omnitrope, Others.  Genotropin dominates the brand segment due to its strong market presence and established reputation for efficacy in growth hormone therapy.

By Route of Administration

Based on Route of Administration, the market has been divided into Subcutaneous, Intramuscular, Intravenous, Oral, Others. subcutaneous administration dominates the route of administration segment due to its ease of use and effectiveness in delivering growth hormone therapies.

By Application

Based on the Application, the market has been divided into Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome, Prader-Willi Syndrome, Others. Growth Hormone Deficiency (GHD) dominates the application segment, as it is the primary indication for growth hormone therapies and encompasses a broad patient base.

By Distribution Channel

Based on Distribution Channel, the market has been divided into Hospital Pharmacies, Retail Pharmacies, Clinics, E-Commerce Websites, Others. hospital pharmacies dominate the distribution channel segment due to their role in providing specialized medications and comprehensive patient care for chronic conditions.

Global Growth Hormone Deficiency Market Regional Analysis

Based on region, the market has been divided into North America, Europe, Asia-Pacific, the Middle East & Africa, and Latin America. The area of North America is anticipated to dominate the market for the usage of Growth Hormone Deficiency, followed by those in Asia-Pacific and Europe.

Growth Hormone Deficiency North America Market

The North American region holds a dominant position in the Growth Hormone Deficiency market. In 2022, the growth hormone deficiency market in America held the biggest market share. Its substantial stake is mainly due to the region’s abundance of market participants, growing technology advancements, and well-developed healthcare infrastructure.

Growth Hormone Deficiency Asia Pacific Market

The Asia-Pacific region is witnessing rapid growth and emerging as a significant market for the Growth Hormone Deficiency industry. The market for growth hormone deficiency is anticipated to expand at the quickest rate in the Asia-Pacific region between 2023 and 2032 as a result of rising treatment advancements, more funding for research, and an increase in the prevalence of GHD. Furthermore, the growth hormone deficiency market in China accounted for the greatest market share, while the market in India is anticipated to grow at the fastest rate in the Asia-Pacific region.

Competitive Landscape

The competitive landscape includes key players (tier 1, tier 2, and local) having a presence across the globe. Companies such as Novo Nordisk A/S, Pfizer Inc, Novartis AG, Anhui Anke Biotechnology (Group) Co., Ltd, and Biopartners GmbH are some of the leading players in the global Growth Hormone Deficiency Industry. These players have adopted partnership, acquisition, expansion, and new product development, among others as their key strategies.

Key Market Players:

• Novo Nordisk A/S
• Pfizer Inc
• Novartis AG
• Anhui Anke Biotechnology (Group) Co., Ltd
• Biopartners GmbH
• Ipsen S.A.
• Eli Lily And Company
• Merck KGaA
• GeneScience Pharmaceuticals Co., Ltd
• Lifetech Labs

Key Development:

In September 2020, Novo Nordisk received US Food and Drug Administration approval for Sogroya (somapacitan). The drug is used in the treatment of adults suffering from growth hormone deficiency.

Scope of the Report

Global Growth Hormone Deficiency Market, by Brands

• Genotropin
• Norditropin
• Humatrope
• Saizen
• Omnitrope
• Others

Global Growth Hormone Deficiency Market, by Route of Administration

• Subcutaneous
• Intramuscular
• Intravenous
• Oral
• Others

Global Growth Hormone Deficiency Market, by Application

• Growth Hormone Deficiency
• Idiopathic Short Stature
• Small for Gestational Age
• Turner Syndrome
• Prader-Willi Syndrome
• Others

Global Growth Hormone Deficiency Market, by Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Clinics
• E-Commerce Websites
• Others

Global Growth Hormone Deficiency Market, by Region

• North America
  • US
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Benelux
  • Nordic
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • South Korea
  • Indonesia
  • Austalia
  • Malaysia
  • India
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Egypt
  • South Africa
  • Rest of Middle East & Africa

 

Parameters	Indicators
Market Size	2033: $6.21 Billion
CAGR	4.94% CAGR (2023-2033)
Base year	2022
Forecast Period	2023-2033
Historical Data	2021
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Key Segmentations	Brands, Route of Administration, Application, Distribution Channel
Geographies Covered	North America, Europe, Asia-Pacific, Latin America, Middle East, Africa
Key Vendors	Novo Nordisk A/S, Pfizer Inc, Novartis AG, Anhui Anke Biotechnology (Group) Co., Ltd, Biopartners GmbH, Ipsen S.A., Eli Lily And Company, Merck KGaA, GeneScience Pharmaceuticals Co., Ltd, Lifetech Labs
Key Market Opportunities	Strong pipeline of hormonal drugs Easy availability of pharma drugs on E-commerce platforms
Key Market Drivers	Increasing cost of GHD Increasing counterfeit products for GHD treatment Rising number of strategic initiatives

 

REPORT CONTENT BRIEF:

• High-level analysis of the current and future Growth Hormone Deficiency Industry trends and opportunities
• Detailed analysis of current market drivers, restraining factors, and opportunities analysis in the future
• Historical market size for the year 2021, and forecast from 2023 to 2033
• Growth Hormone Deficiency market share analysis for each segment
• Competitor analysis with a comprehensive insight into its product segment, financial strength, and strategies adopted.
• Identifies key strategies adopted by the key players including new product development, mergers and acquisitions, joint ventures, collaborations, and partnerships.
• To identify and understand the various factors involved in the global Growth Hormone Deficiency market affected by the pandemic
• To provide year-on-year growth from 2022 to 2033
• To provide short-term, long-term, and overall CAGR comparison from 2022 to 2033.
• Provide Total Addressable Market (TAM) for the Global Growth Hormone Deficiency Market.